Reply to the commentary on “Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis”

IF 8.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-22 DOI:10.1016/j.euroneuro.2025.11.003

Natalia E. Fares-Otero , Monika Budde , Jonathan Laatsch , Mathias Harrer , Teuntje Pelgrim , Alexandra Philipsen , Urs Heilbronner , Eduard Vieta , Roos van Westrhenen , PSY-PGx Consortium

引用次数: 0

查看原文本刊更多论文

回复“药物遗传学（PGx）指导的抗抑郁治疗对焦虑和情感障碍成人的功能结局和生活质量的疗效：系统回顾和荟萃分析”的评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Neuropsychopharmacology 医学-精神病学

CiteScore

10.30

自引率

5.40%

发文量

730

审稿时长

41 days

期刊介绍： European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.